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Background: In severe coronary artery disease, coronary artery bypass grafting (CABG) surgery is indicated to
re-establish an adequate blood supply to the ischemic myocardium. Effectiveness of CABG surgery for symptom
relief and mortality decrease should therefore depend on bypass graft patency. As bypass using a left internal
mammary artery (LIMA)-to-left anterior descending coronary artery (LAD) anastomosis allows the best results in
terms of graft patency, we designed a new surgical technique using a saphenous vein graft as a venous bridge to
distribute the LIMA flow to the cardiac anterolateral territory. This novel strategy could extend the patency benefits
associated to the LIMA. Other potential benefits of this technique include easier surgical technique, possibility to
use saphenous vein grafts as vein patch angioplasty, shorter saphenous vein grafts requirement and reduced or
eliminated manipulations of the ascendant aorta (and associated stroke risk).
Methods/Design: Between July 2012 and 2016, 200 patients undergoing a primary isolated CABG surgery using
cardiopulmonary bypass with a LAD bypass graft and at least another target on the anterolateral territory will be
randomized (1:1) according to 1) the new composite strategy and 2) the conventional strategy with a LIMA-to-LAD
anastomosis and revascularization of the other anterolateral target(s) with a separated aorto-coronary saphenous
vein graft. The primary objective of the trial is to assess whether the composite strategy allows non-inferior
anterolateral graft patency index (proportion of non-occluded CABGs out of the total number of CABGs) compared
to the conventional technique. The primary outcome is the anterolateral graft patency index, evaluated at one year
by 256-slice computed tomography angiography. Ten years of clinical follow-up is planned to assess clinical
outcomes including death, myocardial infarction and need for revascularization.
Discussion: This non-inferiority trial has the potential to advance the adult cardiac surgery field, given the potential
benefits associated with the composite grafting strategy.
Trial registration: ClinicalTrials.gov: NCT01585285.
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In severe coronary artery disease, coronary artery bypass
grafting (CABG) surgery is indicated to re-establish an ad-
equate blood supply to the ischemic myocardium [1,2]. It
reduces morbidity and mortality in patients with left main,
triple-vessel disease and/or proximal stenosis of the left
anterior descending coronary artery (LAD) compared to
medical therapy [2-4], and decreases coronary repeat re-
vascularization rate in comparison to percutaneous coro-
nary intervention [2,5]. Advances in medical therapy for
ischemic heart disease and heart failure have improved the
outcomes of patients with coronary artery disease. The sur-
vival advantage of CABG surgery over medical therapy in
patients with stable angina has been challenged [6] and is
the subject of the ongoing ISCHEMIA trial (ClinicalTrials.
gov: NCT01471522).
Effectiveness of CABG surgery is directly related to graft
patency [2,7]. Best graft patency is obtained using the left
internal mammary artery (LIMA) for the LAD territory,
while saphenous vein graft (SVG) patency is comparatively
inferior [2]. In order to expand the LIMA reach to a larger
cardiac territory, we conceived a composite CABG strat-
egy: a short SVG used as a venous bridge is sequentially
interposed between the LAD and the other target(s) of the
cardiac anterolateral territory, and the LIMA is anasto-
mosed on the venous bridge, immediately above the
SVG-to-LAD anastomosis (LIMA-saphenous vein bridge
strategy; LSVB). In this set-up, the saphenous vein bridge
acts as a venous angioplasty at the level of the LAD
allowing easier anastomosis of the LIMA for the LAD and
secondary distribution of the inflow to the other anterolat-
eral target(s) anastomosed to the saphenous vein bridge.
Therefore, this novel CABG technique could allow exten-
sion of the LIMA patency advantages while preserving the
LIMA flow to the LAD, which was proven important to
improve patient survival [8,9].
In a pilot study with 256 patients (mean follow-up of
3 years), we demonstrated the feasibility and security of
the new CABG technique [10]. Incidences of clinical
events (mortality, myocardial infarction (MI), low car-
diac output syndrome, re-exploration for bleeding and
recurrence of angina) over the short and long term were
low. The graft patency of 20 patients operated according
to the LSVB strategy was assessed in a sub-study using
256-slice computed tomography (MSCT) angiography
after a mean follow-up of 51 months [10]. The 256-slice
MSCT angiography is a non-invasive imaging technique
that allows comprehensive and objective assessment of
grafts and coronary arteries with an elevated diagnostic
accuracy [11-14]. We demonstrated that the LIMA-LAD
axis patency index (that is, proportion of non-occluded
LIMA-LAD out of the total number of LIMA-LAD) was
100%. The anterolateral patency index (including CABG
to the LAD and the other anterolateral target(s)) was93% compared to the aorto-coronary SVG patency index
to other cardiac territories of 87% (P = 0.47).
Numerous potential benefits for the composite strategy
have been identified during the preliminary studies: 1)
SVG-to-LAD anastomoses are less technically complex to
perform, compared to LIMA-to-LAD anastomoses when
the LAD is severely atherosclerotic, calcified, small or pro-
foundly intramyocardial, or in comparison with sequential
anastomoses of the LIMA on a diagonal coronary artery
in a side-to-side fashion before joining the LAD with an
end-to-side anastomosis, with the risk of compromising
the LIMA integrity and distal flow; 2) the SVG can be
used as a vein patch angioplasty when the anterolateral
coronaries are severely diseased, which is more difficult to
perform with LIMA only; 3) manipulations of the ascen-
dant aorta (and associated stroke risk) are reduced, or
even eliminated, when the CABG surgery is done as part
of an off-pump surgery in which no aorto-coronary graft
is needed; 4) arterial conduits can be saved to graft larger
territories (that is, territories of the circumflex artery and
right coronary artery) than the often smaller territories of
anterolateral targets other than the LAD; 5) as the SVG
required to revascularize the anterolateral territory is
shorter, it is possible to select the most favorable saphe-
nous vein portion to be used as the graft, hence allowing a
lower chance of having a diseased SVG portion where the
endothelium could have been injured during harvesting;
and 6) a more complete revascularization can be per-
formed in patients with saphenous vein or arterial con-
duits limited supply.
The short- and long-term graft patency results obtained
with the conventional CABG strategy are already particularly
good [2]; LIMA to LAD and SVG patency index at one year
in trials including patients undergoing isolated CABG sur-
gery with cardiopulmonary bypass (CPB) are 96% and 85%,
respectively [15-22]. These published graft patencies are
comparable to those obtained using other grafting strategies,
including total arterial grafting [23,24]. We hypothesized
that the LSVB technique could allow a non-inferior, but not
necessarily superior, graft patency. As this technique pre-
sents the interesting potential benefits stated above, a non-
inferiority design was chosen for the study.
To date, few studies discussed the results obtained after
a coronary revascularization surgery in which a SVG is
used as a composite graft with the LIMA [25-32], and only
one exposed a surgical technique somewhat similar to the
one we present [28]. Certain surgeons criticize the LSVB
technique saying that the interposition of a short portion
of SVG between the LIMA and the LAD could be deleteri-
ous for the LIMA flow distribution to the LAD, supplying
an important part of the left ventricle [33], if the SVG
should occlude or should a flow competition establish be-
tween the LAD and the other anterolateral target(s).
The AMI-PONT prospective randomized clinical non-
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The AMI-PONT trial (ClinicalTrials.gov: NCT01585285)
is a prospective single center non-inferiority randomized
clinical trial with parallel groups and a 1:1 allocation ratio.
The unit of randomization will be the patient while the
unit of analysis will be the CABGs, which will be ≥2 by pa-
tient (see below).
Participants
Patients will be eligible if they are more than twenty-one
years old and have to undergo a primary isolated CABG
surgery with median sternotomy and bypass of the LAD
and at least one other suitable anterolateral target. This tar-
get can be another site on the LAD, a ramus intermedius,
any suitable diagonal branch (diameter >1 millimeter) of
the LAD or a high first marginal branch of the left circum-
flex coronary artery. Targets must present a proximal ste-
nosis of ≥70% (or ≥50% for left main) with an adequate
outflow bed according to the surgeon. Patients will be ex-
cluded if the LIMA is unusable, such as in uncorrected
subclavian artery stenosis, anterior chest trauma or radi-
ation, or injury during harvesting contraindicating its use.
Patients with a disease potentially limiting their life expec-
tancy to less than two years, a congestive heart failure with
a left ventricular ejection fraction <30%, a contraindication
to CPB (that is, calcified aorta) or deemed not suitable for
both techniques at the time of surgery by the operating
surgeon including planned total arterial revascularisation
will not be randomized. Candidates with a contraindication
to MSCT angiography will be excluded: moderate to severe
renal failure (estimated glomerular filtration rate <50 mL/
min/1.73 m2), chronic atrial fibrillation, history of severe
hypersensibility to an iodinated contrast agent, known or
suspected pheochromocytoma, pregnant or breastfeeding
female, or severe congestive heart failure (New York Heart
Association (NYHA) class IV) unlikely to improve follow-
ing CABG surgery. At the time of the MSCT angiography,
patients will be excluded for the graft patency assessment
of the trial if they present persistent rapid (>100
beats/minute) atrial fibrillation or any other cardiac rhythm
precluding reliable electrocardiogram (ECG) gating, or a
severe congestive heart failure (NYHA class IV) despite
coronary revascularization and maximal medical treatment.
The AMI-PONT research project was approved by the
Centre hospitalier de l’Université de Montréal Research
Ethics Committee in April 2012. Eligibility of every patient
planned to undergo a CABG surgery at our institution will
be assessed. The project will be proposed to every patientsmeeting the inclusion and exclusion criteria and a written
informed consent will be obtained for each participant.
The process of enrollment and randomization is showed
in Figure 1.
Randomization: allocation concealment and
sequence generation
Randomization will be performed during surgery when
the surgeon will confirm, after the sternotomy and expo-
sure of the great vessels, the SVG and LIMA harvesting,
and the determination of the anterolateral targets, that it
would be safe to perform a CPB surgery using either a
conventional or LSVB strategy (the target(s) on the LAD
and the other anterolateral target(s) must be aligned in
order to avoid a bridge torsion if the patient had to be
randomized to a LSVB technique). Randomization will be
determined with an opaque sealed envelope. Permuted
random blocks of four, six and eight for each participating
surgeon will be used and will be stratified in time and by
surgeon. The allocation sequence will be created when the
research coordinator will draw an envelope in a block
associated to the surgeon before the operation of each
enrolled patient. Envelopes will be prepared before the
enrollment of the first patient.
Interventions
CABG surgeries will be performed through a median
sternotomy using standard CPB with blood cardioplegia
under mild hypothermia (34°C) after operative risk evalu-
ation using the Society of Thoracic Surgeons score and
EuroSCORE II. Aspirin will be administrated until day of
surgery. Clopidogrel and ticagrelor will be discontinued
at least 5 days before surgery with prasugrel being dis-
continued at least 7 days before surgery, unless the surgery
is urgent. In order to control for potential bias in patency
results according to the use of an on-pump versus an off-
pump grafting strategy, all patients will undergo CABG
surgery using CPB (on-pump). We recognize that one of
the potential benefits of a LSVB grafting strategy is avoid-
ance of ascending aorta manipulation if the surgery is
performed without cardiopulmonary bypass (off-pump)
and no aorto-coronary grafts are needed, but recruitment
of off-pump patients would expose the trial to a potential
5 to 10% conversion rate to on-pump CABG surgery.
In the conventional strategy (Figure 2), the in situ LIMA,
harvested in pedicle, will be anastomosed in an end-to-side
fashion to the LAD, after the occluded or stenosed coro-
nary portion. If there is only one other target on the an-
terolateral territory, this target will be bypassed using a
SVG anastomosed proximally on the ascendant aorta (that
is, aorto-coronary bypass). If there are two or more antero-
lateral targets other than the LAD, sequential bypass grafts
will be completed (that is, more than a bypass by graft, in
series) with the sequential SVG anastomosed on the as-
cendant aorta.
Figure 1 Study design. CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; LIMA, left internal mammary artery; MSCT,
multislice computed tomography.
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connect the anterolateral territory targets, including the
LAD. If there is only one other anterolateral target than
the LAD, a SVG will be anastomosed to these two coro-
nary arteries in an end-to-side manner. If there are two or
more anterolateral targets other than the LAD, targets
between the LAD and the opposite end of the venous
bridge will be anastomosed sequentially to the venous
bridge with side-to-side anastomoses. Then, the in situ
LIMA, harvested in pedicle, will be anastomosed on the ven-
ous bridge, as close as possible to the SVG-to-LAD anasto-
mosis, in order to maximally reduce the SVG interposition
between the LIMA and the LAD. Hence, blood flow supplied
by the LIMA will almost directly supply the LAD, via the
interposition of a small portion of SVG, and the other an-
terolateral target(s) backwards, via the venous bridge.
For both strategies, if other coronary arteries elsewhere
than in the anterolateral territory have to be bypassed,
CABGs will be performed according to the surgeon prefer-
ences, but they will not communicate with the anterolateral
grafts. For each coronary target, graft anatomy details
will be noted (length, diameter and quality). At the end
of the surgery (that is, after protamine administration),graft flow characteristics will be recorded by protocol
using a VeriQ Flowmeter System (MediStim ASA,
Horten, Norway) for all grafts.
Objectives
The primary objective of the trial is to assess whether a
CABG surgery performed with a LSVB technique allows
non-inferior anterolateral graft patency index compared
to a conventional strategy.
Outcomes
The primary outcome is the anterolateral graft patency
index, evaluated at 1 year by 256-slice MSCT angiography.
Secondary outcomes include 1) patency of each graft, eval-
uated at 1 year by 256-slice MSCT angiography; 2) free-
dom from death, new target vessel revascularization (redo
CABG surgery or percutaneous coronary intervention)
and myocardial infarction at 30 days, 3 months, 6 months,
1 year, 5 years and 10 years; 3) correlation between LIMA,
saphenous bridge and SVG transit time Doppler flow data
at the time of surgery (VeriQ Flowmeter System, MediStim
ASA, Horten, Norway) and graft patency at one year, and
clinical outcomes at 30 days, 1 year, 5 years and 10 years; 4)
Figure 2 Conventional strategy. The in situ left internal mammary
artery is directly anastomosed to the left anterior descending coronary
artery (LAD) and a separated aorto-coronary saphenous vein graft is
anastomosed to the anterolateral target(s) other than the LAD. A
magnified detail of the distal anastomoses is provided in the left upper
corner of the figure. The distal portion of the left internal mammary
artery (LIMA) pedicle has been graphically removed in order to present
a better view of the distal anastomosis. SVG, saphenous vein graft.
Figure 3 Left internal mammary artery-saphenous vein bridge
strategy. The in situ left internal mammary artery (LIMA) and a
saphenous vein bridge are used compositely to distribute the LIMA
flow to the anterolateral territory. A magnified detail of the distal
anastomoses is provided in the left upper corner of the figure. The
distal portion of the LIMA pedicle has been graphically removed in
order to present a better view of the distal anastomosis. LAD, left
anterior descending coronary artery; SV, saphenous vein.
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follow-up is planned to assess long-term survival.
Clinical events will be ascertained throughout follow-up
using predetermined definitions and will be assessed by
blinded adjudicators. Clinical events of interest include
total mortality, cardiovascular death, recurrence of angina,
perioperative (<48 hours) and other postoperative MI, and
need for repeated coronary revascularization.
An external Data and Safety Monitoring Board will
regularly assess data to insure patient safety according to
early- and mid-term clinical outcomes.
Outcomes measurement
Follow-up
Randomized patients will be met in an outpatient visit
30 days after surgery to evaluate occurrence of clinicalevents, and Canadian Cardiovascular Society (CCS) and
NYHA scores. They will then be called 3 months,
6 months, 1 year and 5 years after surgery to assess clin-
ical events occurrence, and CCS and NYHA scores. In
addition, clinical data, including cardiac events, re-
hospitalizations, procedures and survival status, will be
obtained up to twelve years after surgery in order to as-
sure a mean follow-up of ten years, using the provincial
health insurance plan registry of the Régie de l’assurance
maladie du Québec for which patients will have consented
at the study onset.
Multislice computed tomography angiography
MSCT angiography will be performed at 1 year ± 4 months
following CABG surgery. Images will be acquired with
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spective ECG-gating and a gantry rotation time of 270 mil-
liseconds. Heart rate control is primordial to obtain
superior image quality and for radiation dose reduction. In
order to achieve a ≤60 beats/minute heart rate, patients
with a heart rate >60 beats/minute will receive an oral
β-blocker or calcium-channel blocker. Sublingual nitrogly-
cerine will be given 2 minutes before the MSCT angiog-
raphy to increase coronary lumen and hence allow greater
visualization. Acquired images will be processed using the
TeraRecon thin client post-processing software (Aquarius
intuition edition version 4.4.4.23.771, Foster City, California,
United States).
For interpretation, each graft will be separated into three
sections that will be distinctively assessed: graft body, prox-
imal or distal anastomosis, and distal native coronary bed.
The image quality of each section will be evaluated before
interpretation. A graft will be considered occluded if not
opacified on native images and post-processing in the pres-
ence of a good opacification of other arterial structures.
When assessable, lesion severity will be assessed using a
four-point scale: 1) normal lumen (0 to 49% stenosis);
2) moderate stenosis (50 to 69%); 3) severe stenosis (70 to
99% stenosis or string sign (graft diameter <2 mm));
4) graft occlusion (100%).
Blinding
Because the surgical technique is different for the two pro-
posed CABG strategies, the surgeon, staff of the operating
room and of the postoperative yards, and people collecting
the intraoperative data will not be blinded to the
performed strategy. Randomized patients will not neces-
sarily be blinded either because in view of the Public Hos-
pital’s Act and Regulations, details of the operation must
be collected in the patient’s chart when the patient leaves
the operating room. Cardiologists assessing clinical events
(MI) and the statisticians who will analyze the results will
be blinded to the performed surgical technique. The radi-
ologists reading the MSCT angiographies will not be
blinded to the surgical mapping, which is readily obvious
to them even if they do not have access to it, but they will
be blinded to the clinical condition of the patient.
Sample size
Based on published data, the 1 year LIMA and SVG graft
patency index are 96% and 85%, respectively [15-22].
Based on our experience [10], 2.15 grafts on average are
required on the anterolateral territory (that is, for about
15% of patients >2 grafts will be performed on the antero-
lateral territory). We can estimate the graft patency index
for all anterolateral grafts in the conventional group with
separate LIMA-LAD and SVG to anterolateral coronary
targets at ((96% + (1.15 x 85%))/2.15) = 90%. The antero-
lateral graft patency index in the LSVB group was 93% at
a mean follow-up of 51 months [10]; therefore, theexpected patency index at 1 year should be ≥93% although
most stenosis and occlusions are expected to occur within
the first year after surgery. The power analysis is based on
a non-inferiority principle, justified by the potential bene-
fits of the LSVB technique, namely increased flow through
the LIMA, easier surgical technique and shorter saphe-
nous vein grafts requirement. A predetermined 5% non-
inferiority margin was defined based on the smallest
decrease in graft patency for anterolateral grafts that the
surgeons would be willing to accept considering the iden-
tified benefits. Non-inferiority of the LSVB technique will
be accepted if the upper bound of the 97.5% confidence
interval for the estimated difference in the anterolateral
graft patency index lies below 5%. If there is a true differ-
ence in favor of the LSVB CABG strategy of 3%, then a
total of approximately 430 anterolateral coronary grafts, or
200 patients (randomized 1:1), are necessary to establish
non-inferiority of LSVB compared to conventional CABG
strategy [34,35] for both the intention-to-treat and per-
protocol analyses, assuming a one-sided 2.5% alpha
with ≥80% power and a sample size inflation of 10% to
account for grafts not analyzable by MSCT, patient drop-
out and correlated graft patency results in the same patient.
This will allow us to be ≥80% sure that the upper limit of a
one-sided 97.5% confidence interval (or equivalently a 95%
two-sided confidence interval) will exclude a difference in
favor of the conventional surgical technique of ≥5%.
Statistical methods
A two-tailed P value of 0.05 will be considered signifi-
cant. Methodologically, the study will be conducted and
reported according to recommended guidelines (CON-
SORT [36]). For the graft patency outcome assessment,
the unit of analysis will be the graft while the unit of
randomization is the patient. Sequential grafts will count
for as many grafts as there are distal anastomoses. Logis-
tic or ordinal multilevel models, with a random effect
for the patient, will be used to account for the corre-
lation between patency results for grafts performed in
the same patient. For the primary non-inferiority out-
come, patients will be analyzed A) according to the
intention-to-treat principle, in which all participants are
included in their assigned treatment groups regardless of
actual surgical procedure performed, and B) according
to per-protocol principle, in which only patients where
surgery was completed according to the protocol are in-
cluded, in order to control for the bias that arises when
patient crossover renders patient groups more similar with
a greater chance of claiming non-inferiority. Graft patency
results will be presented as number and percentage with
95% confidence interval including graphically the prede-
termined 5% non-inferiority margin. Superiority of the
LSVB strategy will also be assessed as a secondary ob-
jective if non-inferiority is demonstrated. No multiple-
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ses tests approach [37]. The intention-to-treat principle
will guide the superiority hypothesis test for the main
outcome of interest and other secondary outcome
analyses [36-38]. Graft occlusion risk factors will be
assessed using multilevel logistic regression models. The
analyses will also be performed at the level of the patient,
assessing the proportion of patients with any occluded
bypass graft in the anterolateral territory or elsewhere.
In the clinical outcome analyses, time to event analysis
using Kaplan-Meier method, log-rank tests and Cox regres-
sion will be the preferred methods. If proportional hazards
assumption is violated, we will use both logistic regression
and Cox regression with time-dependent covariates with
Aalen’s additive hazards model. Participants who prema-
turely discontinue follow-up before a major cardiovascular
event will be censored as to their last follow-up data. The
effect of the two operative techniques on different sub-
groups (that is, the effect of the two operative techniques
on graft patency for different subgroups defined by dia-
betes, left ventricular function, number of vessels diseased,
gender, age, EuroSCORE II (3 to 5 and ≥5) and use of
certain medications (clopidogrel and statins) or sequential
grafting) will be conducted by stratified analysis through a
multilevel logistic regression or multilevel Cox propor-
tional hazards model, as appropriate.
Potential selection bias can be expected from patients ex-
cluded from MSCT assessment because of patient refusal,
death or loss to follow-up. Sensitivity analysis will
be conducted by including excluded patients in the analysis
of the percentage of patients with at least one occluded
graft, assuming, hypothetically, that the excluded patients
present at least one occluded anterolateral grafts. We willFigure 4 Possible trial outcomes. Potential study outcomes are presente
index between the two study groups with a 95% confidence interval for thassess whether the conclusion reached by this sensitivity
analysis is similar to the conclusion reached with the
analyses of MSCT patients alone.
Discussion
Hypotheses and possible trial outcomes
In non-inferiority trials, the null and alternative hypoth-
eses are reversed compared to superiority trials [36].
Hence, the null hypothesis supposes that there is a dif-
ference between the compared treatments and the alter-
native hypothesis presumes that treatments do not differ,
which means that the new treatment is non-inferior to
the conventional one(s).
In the AMI-PONT trial, the null (H0) and the alterna-
tive (HA) hypotheses are:
 H0: N - C ≤ −Δ (that is, the anterolateral graft
patency index in the new grafting strategy group (N)
is not non-inferior to the one in the conventional
CABG strategy group (C) by a pre-defined non-
inferiority margin of -Δ% or less, where Δ = 5 for
this trial, or non-inferiority is not shown.)
 H1: N - C > −Δ (that is, the anterolateral graft patency
index in the new grafting strategy group is non-inferior
to the one in the conventional CABG strategy group.)
According to a non-inferiority study design, five trial
outcomes are possible (Figure 4). For non-inferiority to
be demonstrated (cases i, ii, and iii), the point esti-
mate and the 95% confidence interval of the differ-
ence in anterolateral graft patency index between the
new and conventional grafting group have to be
greater than the non-inferiority margin of −5%. Ifd with point estimate for the difference in anterolateral graft patency
e difference. See text for details. CABG, coronary artery bypass grafting.
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1) non-inferiority and superiority, in which the point
estimate and the confidence interval completely stand
over 0% (case i); 2) non-inferiority and non-superiority,
in which the point estimate lies above −5% and the
confidence interval includes 0%, but not −5% (case ii);
3) non-inferiority and inferiority, in which the point esti-
mate and the entire confidence interval are between −5%
and 0% (case iii). Non-inferiority will not be shown if the
confidence interval includes both the −5% non-inferiority
margin and the 0% lines (case iv). Finally, inferiority will
be established if the point estimate and the confidence
interval completely stand below the −5% line (case v).
Limitations
The trial potential limitations are addressed as fol-
lows. First, surgeons, staff of the operating room and
of the postoperative yards, personnel collecting the
intraoperative data, and patients, will not be blinded
to the surgical strategy performed. However, as the
two CABG techniques are regularly practiced at our
institution and their postoperative managements are
similar, we do not foresee any impact of this non-
blinding on the results. Second, to limit the operator
bias, surgeries will be performed by four surgeons
who perform both surgical strategies on a routine
basis with an average of more than a hundred CABG
surgeries done each year, and the surgical technique
will be clearly standardized between surgeons. More-
over, as randomization will be stratified by surgeon,
each surgeon will practice as many of both surgical
strategies. Third, in order to limit the clinical out-
comes assessment bias, each outcome is clearly de-
fined and determined by blinded evaluators. Fourthly,
as the primary outcome, anterolateral patency index
at one year, is a combined outcome, interpretation
bias could arise from the fact that it will be difficult
to distinguish from this composite measure if the
occluded graft sections (LAD or non LAD segment)
differ according to the strategy used. To remedy to
this potential bias, patency of each graft taken separately
will be assessed as a secondary outcome. Finally, patients
with renal failure and/or calcified aorta will be excluded
because of contraindication to MSCT and impossibility
to practice both type of CABG surgery, respectively.
Although they could beneficiate from a LSVB strategy,
this trial will not provide data specifically for these
populations.
Trial potential impact
If the trial demonstrates the non-inferiority of the novel
grafting strategy, it could have an important impact on the
adult cardiac surgery field, given the potential benefits of
the LSVB technique. As we are faced with increasinglyolder patients presenting important comorbidities and
poorer coronary targets, this population could benefit
from this surgical alternative, allowing in some patient
subsets a more optimal operation potentially leading to
better overall results.
Trial status
The recruitment began in July 2012 and is expected to
take 3 to 4 years (ending in 2015 to 2016).
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